• Immunovia’s PancreaSure study results will be presented November 3, 2026, during a Presidential Plenary at the CGA-IGC annual meeting in Denver.
• The retrospective analysis found the blood test performed well in distinguishing early-stage pancreatic cancer from controls at hereditary or familial risk.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunovia AB published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.